Structure/Function vs. Disease Claims: Where FDA Draws the Line for Dietary Supplements
Claims are a major component involved in FDA dietary supplement regulation in the United States. They influence how products are classified, how they are reviewed, and how enforcement decisions are made. For growing brands, claim language often develops through marketing, education, and content workflows before regulatory risk is considered in full.
Claims and How Dietary Supplements Are Regulated in the United States
Under U.S. law, dietary supplements occupy a specific category that allows certain claims without pre‑approval by FDA. That allowance is not unlimited. The Dietary Supplement Health and Education Act of 1994 established supplements as a food category and permitted structure/function claims when specific conditions are met. The Federal Food, Drug, and Cosmetic Act governs misbranding and defines when products are treated as unapproved drugs based on intended use.
From a marketing perspective, this distinction matters. Supplements may describe how ingredients support normal structure or function of the body. Claims tied to diagnosing, treating, curing, or preventing disease fall outside that category and shift regulatory classification.
Structure and Function Claims Under DSHEA
Structure/function claims are defined in FDA regulation and guidance. They describe the role of a nutrient or ingredient on normal body structure or function, may reference general well‑being, and may describe support related to nutrient deficiency diseases when required disclosures are included. FDA has cited examples such as calcium building strong bones, fiber supporting digestive regularity, and antioxidants maintaining cell integrity.
When a structure/function claim is used, labeling must include a specific disclaimer stating that the claim has not been evaluated by FDA and that the product is not intended to diagnose, treat, cure, or prevent disease. The presence of this disclaimer does not change how FDA evaluates the claim language itself. FDA reviews the words used, their context, and how they are likely to be understood.
Another requirement that is often missed involves structure/function claim notification. Manufacturers must submit a notification to FDA within thirty days of first marketing a product bearing the claim. That submission includes the exact claim text and a certification that the claim is truthful and not misleading. Using claims before this notification is submitted can expose products to misbranding risk.
Disease Claims and FDA Drug Classification
Disease claims are treated differently. FDA considers any statement that explicitly or implicitly claims to diagnose, mitigate, treat, cure, or prevent disease to be a drug claim by intent. This includes references to specific diseases, abnormal conditions, or recognizable signs and symptoms associated with disease.
FDA’s evaluation does not focus on individual words in isolation. Review considers the full context, including websites, social media, FAQs, and the combined effect of multiple statements. Consumer takeaway plays a central role. Language that rephrases disease claims using terms such as support, balance, or optimize still receives scrutiny when the overall message suggests disease treatment.
FTC Advertising Oversight and Substantiation
Advertising oversight adds another layer through the Federal Trade Commission. The FTC regulates supplement advertising and requires that claims be truthful, not misleading, and substantiated before dissemination. The FTC applies a competent and reliable scientific evidence standard and evaluates claims based on how consumers are likely to interpret them. Claims that satisfy FDA labeling standards may still present risk under FTC advertising law.
Recent enforcement actions reflect this overlap. FDA and FTC have jointly addressed situations where products labeled as supplements were marketed with disease claims. These cases illustrate how claim language can trigger multiple regulatory pathways at once.
Where Many Teams Draw the Line Internally
For internal alignment, many teams rely on a simple rule. If a reasonable consumer could believe a product treats a disease, FDA is likely to reach the same conclusion, regardless of disclaimers or intent.
Understanding where this line is drawn requires shared training across marketing, operations, and leadership. That shared understanding is often where preparedness begins.
Interested in learning about our certification? Click the button below to learn more and claim your spot.
Disclaimer: All information and content found on this website is for educational and informational purposes only and should not be considered medical advice, legal advice, or health advice. Information on this website should not be used as a substitute for medical advice, diagnosis, or treatment from your licensed healthcare professional. Sincerely PharmD LLC and Sincerely PharmD LLC employees and/or writers are not your healthcare provider. Always consult your healthcare provider for diagnosis, treatment, and medical advice prior to making any changes to your healthcare regimen. Do not delay seeking medical advice from your healthcare provider based on information obtained from this website